Biotech bears tend to outnumber the bulls at any given time -- and the present is no exception, with dealmaking activity down significantly in 2022, compared with the previous two years.
That's not say the amounts flowing into the industry are meager. Alternatives Watch has tracked more than 50 biotech financing rounds so far in the third quarter. Mainstream private market giants such as Andreessen Horowitz, Warburg Pincus, TPG and Section 32 (see chart below) have become active in the space, according to a recent AW Deal Watch analysis that also found a . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.